Ohio University

Frank L Schwartz

Douglas Goetz

Kelly D McCall

Ramiro Malgor

Leonard D Kohn

Giorgio Napolitano

Norikazu Harii

Uruguaysito Benavides-Peralta

Mariana Gonzalez-Murguiondo

Christopher J Lewis

H Bryan Riley

Mehmet Celenk

Nikita Gurudath

Cesidio Giuliani

Devices and methods for determining a propensity to diabetic and/or macular degeneration in a subject by measuring certain featured from a captured retinal image from a subject are described.

Devices and methods for classifying diabetic and macular degeneration

Methods for preventing, treating, and/or reducing the risk of developing non-alcoholic fatty liver disease in a subject in need thereof and pharmaceutical compositions for the prevention or treatment of non-alcoholic fatty liver disease. Methods for inhibiting excessive accumulation of fat in liver tissue. The methods include administering to the subject or contacting the liver tissue with a therapeutically effective amount of at least one compound of General Formula (I) or General Formula (II): or pharmaceutically-acceptable salts or solvates thereof. The pharmaceutical composition includes at least one compound of the General Formula (I) or the General Formula (II) for administration to a subject for the prevention or treatment of non-alcoholic fatty liver disease. 

Prevention and treatment of non-alcoholic fatty liver disease

Methods for preventing, treating, and/or reducing the risk of developing non-alcoholic fatty liver disease in a subject in need thereof and pharmaceutical compositions for the prevention or treatment of non-alcoholic fatty liver disease. The methods include administering a therapeutically effective amount of phenylmethimazole, methimazole derivatives, and/or tautomeric cyclic thiones to the subject. The pharmaceutical composition includes phenylmethimazole, methimazole derivatives, and/or tautomeric cyclic thiones formulated for administration to a subject for the prevention or treatment of non-alcoholic fatty liver disease.

Treatment of autoimmune and/or inflammatory diseases associated with overexpression of Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. The use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with TLR3 as well as TLR4 and/or TLR3/TLR4 cellular signaling in association with related pathologies is disclosed. Methods of treating a subject having a disease or condition associated with abnormal TLR-3 as well as TLR-4 and/or TLR3/TLR4 cellular signaling in association with related pathologies are also disclosed. The present disclosure also relates to the treatment of autoimmune-inflammatory pathologies and chemokine and cytokine-mediated diseases associated with TLR overexpression and signaling. The disclosure also relates to pharmaceutical formulations capable of inhibiting the IRF-3/Type 1 IFN/STAT/ISRE/IRF-1 pathway associated with Toll-like receptor overexpression or signaling.

Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression

Growing community of inventors

Vienna, WV, United States of America

Frank L Schwartz